Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)
Conditions
Interventions
Intervention1: surgical and non surgical periodontal therapy: Test Group (who are receiving the treatment) receive periodontal intervention and oral hygiene instructions at baseline
Intervention2: Sur
Sponsors
Suhani Maheshwari
Eligibility
Inclusion criteria
Inclusion criteria: Age range: 30-60 years Chronic Kidney Disease Patients suffering from moderate to severe periodontitis Non-smoking (former smokers were included if they had not smoked within 6 months of the study initiation) No periodontal therapy within previous 6 months. Patients who give consent Patients with minimum 20 teeth
Exclusion criteria
Exclusion criteria: History of atherosclerosis involving the coronary cerebral or peripheral vascular systems Experiencing a cardiovascular event (myocardial infarction or stroke) or undergoing coronary angioplasty or peripheral intervention procedure between the Screening Visit and randomization Undergoing any cardiovascular surgery (valvular surgery) within 3 months of study participation Planned revascularization or peripheral intervention procedure or other cardiovascular surgery New York Heart Association (NYHA) Class III or IV heart failure at study participation Patient of End stage renal disease (ESRD)/ patients on hemodialysis or peritoneal dialysis Patients chronically treated (i.e 2 week or more) with any medication that affect periodontal status (i.e antibiotics or non-steroidal anti-inflammatory drugs) or lipid peroxidation with clinically significant or unstable organic diseases or compromised healing potential (i.e. connective tissue disorders or bone metabolic diseases). Pregnant women or lactating. Patients affected by active infectious diseases Asthma Diabetes Immune-compromised or taking steroid medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the level of lipid peroxides-Malondialdehyde (MDA) after periodontal intervention in CKD. Renal Function will be assessed by ACR (Albumin Creatinine Ratio) Timepoint: Change in the level of lipid peroxides-Malondialdehyde (MDA) after periodontal intervention in CKD. Renal Function will be assessed by ACR (Albumin Creatinine Ratio) | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical parameters-Probing Depth (PD) CAL (Clinical attachment Loss) Plaque index(PI) Gingival Index(GI). Change in the level of Inflammatory stress markers after periodontal intervention Timepoint: baseline 6 months and 12 months | — |
Countries
India
Contacts
Public ContactDr Ashish Jain
Dr Harvansh Singh Judge Institute of Dental Sciences and Hospital Panjab University Chandigarh.
Outcome results
None listed